Bio Farma Receives Vaccine Innovation Award, Strengthening Commitment to National Health Resilience



Bandung, November 17, 2026 – PT Bio Farma (Persero), as part of the Danantara Indonesia ecosystem, received the “Domestic Vaccine Development and Innovation” award at the Health Innovation Festival (HAI Fest) 2026 organized by the Ministry of Health of the Republic of Indonesia in Jakarta on November 16, 2026.

The award, presented as part of the 62nd National Health Day commemoration, recognizes Bio Farma’s contribution to advancing innovation and strengthening the capabilities of Indonesia’s vaccine industry. This recognition reinforces the company’s commitment to developing domestic capabilities that support the availability of high-quality vaccines and expand access to health protection across the country.

Indonesia’s Vice Minister of Health, Prof. Dr. Dante Saksono Harbuwono, emphasized that healthcare innovations must provide tangible benefits to society and should not merely remain as products or discoveries displayed at exhibitions.

“Health is a right for everyone, not only for those living in major cities. People in remote, island, and underdeveloped regions must also have equal access,” Dante stated.

This message aligns with Bio Farma’s strategy of strengthening research, technological capabilities, and domestic manufacturing to improve public health protection.

Fitri Puspadewi, Commercial Director of Bio Farma, emphasized that the ability to develop and manufacture vaccines is a strategic foundation for Indonesia's health resilience.

"As part of the Danantara Indonesia ecosystem, Bio Farma is committed to strengthening national capabilities in meeting vaccine needs. We continue to enhance technological expertise, production capacity, and strategic partnerships to gradually reduce dependence on imports while ensuring sustainable supply and wider access to quality vaccines," said Fitri.

In 2026, Bio Farma launched Bio-TCV, a typhoid conjugate vaccine developed through research collaboration, technology transfer, clinical trials, and regulatory evaluation to help prevent typhoid fever caused by Salmonella typhi.

Bio Farma also obtained Marketing Authorization from BPOM for the Nusagard Human Papillomavirus (HPV) vaccine in September and October 2026. Formulation, filling, and packaging are carried out at Bio Farma's facilities, strengthening domestic vaccine manufacturing capabilities.

The company further received BPOM authorization for Bio-RV, a neonatal rotavirus vaccine developed in collaboration with the Murdoch Children's Research Institute (MCRI) to help prevent rotavirus-related diarrhea in infants.

These achievements demonstrate how collaboration with national and global partners strengthens technological mastery and domestic production capabilities while supporting immunization needs and the growth of Indonesia's vaccine industry.

"Investment in vaccine innovation and manufacturing capability is an investment in protecting future generations. We aim to ensure every enhancement of Bio Farma's capabilities strengthens Indonesia's preparedness for health challenges, including pandemics, while creating long-term value for the nation and society," Fitri added.

These efforts are complemented by the company's transformation through improved governance, research and development, production capacity, and collaborative initiatives that support a sustainable vaccine supply.

The HAI Fest 2026 award serves as motivation for Bio Farma to continue delivering innovations that address public health needs and strengthen the foundation of sustainable health resilience for future generations.

HAI Fest 2026 is part of the 62nd National Health Day commemoration series, serving as a platform for appreciation and collaboration among healthcare industry stakeholders in supporting innovation and health transformation in Indonesia.

For Media Information: Corporate Communications, PT Bio Farma (Persero), Corcom@biofarma.co.id

Bandung, November 17, 2026 – PT Bio Farma (Persero), as part of the Danantara Indonesia ecosystem, received the "Domestic Vaccine Development and Innovation" award at the Health Innovation Festival (HAI Fest) 2026 organized by the Ministry of Health of the Republic of Indonesia in Jakarta on November 16, 2026.

The award, presented as part of the 62nd National Health Day commemoration, recognizes Bio Farma's contribution to advancing innovation and strengthening the capabilities of Indonesia's vaccine industry. This recognition reinforces the company's commitment to developing domestic capabilities that support the availability of high-quality vaccines and expand access to health protection across the country.

Indonesia's Vice Minister of Health, Prof. Dr. Dante Saksono Harbuwono, emphasized that healthcare innovations must provide tangible benefits to society and should not merely remain as products or discoveries displayed at exhibitions.

"Health is a right for everyone, not only for those living in major cities. People in remote, island, and underdeveloped regions must also have equal access," Dante stated.

This message aligns with Bio Farma's strategy of strengthening research, technological capabilities, and domestic manufacturing to improve public health protection.

Fitri Puspadewi, Commercial Director of Bio Farma, emphasized that the ability to develop and manufacture vaccines is a strategic foundation for Indonesia's health resilience.

"As part of the Danantara Indonesia ecosystem, Bio Farma is committed to strengthening national capabilities in meeting vaccine needs. We continue to enhance technological expertise, production capacity, and strategic partnerships to gradually reduce dependence on imports while ensuring sustainable supply and wider access to quality vaccines," said Fitri.

In 2026, Bio Farma launched Bio-TCV, a typhoid conjugate vaccine developed through research collaboration, technology transfer, clinical trials, and regulatory evaluation to help prevent typhoid fever caused by Salmonella Typhi.

Bio Farma also obtained Marketing Authorization from BPOM for the Nusagard Human Papillomavirus (HPV) vaccine in September and October 2026. Bio Farma carries out formulation, filling, and packaging at its facilities, strengthening domestic vaccine manufacturing capabilities.

The company further received BPOM authorization for Bio-RV, a neonatal rotavirus vaccine developed in collaboration with the Murdoch Children's Research Institute (MCRI) to help prevent rotavirus-related diarrhea in infants.

These achievements demonstrate how collaboration with national and global partners strengthens technological mastery and domestic production capabilities while supporting immunization needs and the growth of Indonesia's vaccine industry.

"Investment in vaccine innovation and manufacturing capability is an investment in protecting future generations. We aim to ensure every enhancement of Bio Farma's capabilities strengthens Indonesia's preparedness for health challenges, including pandemics, while creating long-term value for the nation and society," Fitri added.

These efforts are complemented by the company's transformation through improved governance, research and development, production capacity, and collaborative initiatives that support a sustainable vaccine supply.

The HAI Fest 2026 award serves as motivation for Bio Farma to continue delivering innovations that address public health needs and strengthen the foundation of sustainable health resilience for future generations.

HAI Fest 2026 is part of the 62nd National Health Day commemoration series, serving as a platform for appreciation and collaboration among healthcare industry stakeholders in supporting innovation and health transformation in Indonesia.

--o0o--

For Media Information:

Corporate Communications

PT Bio Farma (Persero)

Corcom@biofarma.co.id